Indolmycin

Class: Aminoacyl-tRNA synthetase inhibitor (tryptophanyl-tRNA synthetase [TrpS] inhibitor)

Spectrum of activity:	Gram-positive
Details of activity:	Indolmycin is bacteriostatic and demonstrates good activity against MSSA (methicillin-susceptible Staphylococcus aureus), MRSA (methicillin-resistant S. aureus) and VISA (vancomycin-intermediate S. aureus), including strains resistant to mupirocin or fusidic acid.
Institute where first reported:	Chas. Pfizer & Co., Inc., Groton, Connecticut
Year first mentioned:	1980
Highest developmental phase:	Preclinical
Development status:	Active

Chemical structure(s):
Canonical SMILES:	C[C@H](C1=CNC2=C1C=CC=C2)[C@H]3C(=O)NC(=NC)O3
Isomeric SMILES:	C[C@@H]([C@H]1C(=O)NC(=NC)O1)C2=CNC3=CC=CC=C32
InChI:	InChI=1S/C14H15N3O2/c1-8(12-13(18)17-14(15-2)19-12)10-7-16-11-6-4-3-5-9(10)11/h3-8,12,16H,1-2H3,(H,15,17,18)/t8-,12+/m1/s1
InChI Key:	GNTVWGDQPXCYBV-PELKAZGASA-N

External links:
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/135417159
Guide to Pharmacology:	indolmycin
Main Source:	https://aac.asm.org/content/18/6/858.short
Citation:	https://academic.oup.com/jac/article/54/2/549/767563